KalVista Pharmaceuticals, Inc.

NasdaqGM:KALV 株式レポート

時価総額：US$533.3m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

KalVista Pharmaceuticals マネジメント

マネジメント 基準チェック /24

KalVista Pharmaceuticals'の CEO はBen Palleikoで、 Mar2024年に任命され、 の在任期間は 1 年未満です。 の年間総報酬は$ 2.42Mで、 21.3%給与と78.7%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.53%を直接所有しており、その価値は$ 2.75M 。経営陣と取締役会の平均在任期間はそれぞれ3.3年と4.5年です。

主要情報

Ben Palleiko

最高経営責任者

US$6.8m

報酬総額

CEO給与比率8.6%
CEO在任期間less than a year
CEOの所有権0.6%
経営陣の平均在職期間2.3yrs
取締役会の平均在任期間4.5yrs

経営陣の近況

Recent updates

Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?

Sep 12
Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?

KalVista Pharmaceuticals: Looking To Be A Major Player In HAE

Sep 05

Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch

Jun 24

KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)

Feb 14

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Jan 30
We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

Oct 04
We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate

We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully

May 02
We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully

KalVista: Another Setback But The Key Value Driver Is Still In Place

Oct 14

Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation

Sep 24
Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation

KalVista Pharmaceticals GAAP EPS of -$0.94

Sep 08

KalVista reaches five-month high as rival tumbles on hereditary angioedema

Aug 22

KalVista Pharmaceticals GAAP EPS of -$0.98 beats by $0.11

Jul 07

Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?

May 18
Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?

Companies Like KalVista Pharmaceuticals (NASDAQ:KALV) Are In A Position To Invest In Growth

Feb 02
Companies Like KalVista Pharmaceuticals (NASDAQ:KALV) Are In A Position To Invest In Growth

We Discuss Why KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) CEO Compensation May Be Closely Reviewed

Sep 24
We Discuss Why KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) CEO Compensation May Be Closely Reviewed

We're Hopeful That KalVista Pharmaceuticals (NASDAQ:KALV) Will Use Its Cash Wisely

Jul 02
We're Hopeful That KalVista Pharmaceuticals (NASDAQ:KALV) Will Use Its Cash Wisely

KalVista Pharma's oral KVD900 shows rapid improvement in HAE attacks in mid-stage study

Jun 07

CEO報酬分析

KalVista Pharmaceuticals の収益と比較して、Ben Palleiko の報酬はどのように変化したか？
日付総報酬給与会社業績
Jul 31 2024n/an/a

-US$142m

Apr 30 2024US$7mUS$580k

-US$127m

Jan 31 2024n/an/a

-US$108m

Oct 31 2023n/an/a

-US$101m

Jul 31 2023n/an/a

-US$95m

Apr 30 2023US$2mUS$515k

-US$93m

Jan 31 2023n/an/a

-US$91m

Oct 31 2022n/an/a

-US$92m

Jul 31 2022n/an/a

-US$89m

Apr 30 2022US$3mUS$490k

-US$82m

Jan 31 2022n/an/a

-US$73m

Oct 31 2021n/an/a

-US$61m

Jul 31 2021n/an/a

-US$52m

Apr 30 2021US$1mUS$435k

-US$46m

Jan 31 2021n/an/a

-US$38m

Oct 31 2020n/an/a

-US$37m

Jul 31 2020n/an/a

-US$33m

Apr 30 2020US$1mUS$435k

-US$29m

Jan 31 2020n/an/a

-US$31m

Oct 31 2019n/an/a

-US$26m

Jul 31 2019n/an/a

-US$23m

Apr 30 2019US$2mUS$366k

-US$21m

Jan 31 2019n/an/a

-US$13m

Oct 31 2018n/an/a

-US$14m

Jul 31 2018n/an/a

-US$16m

Apr 30 2018US$821kUS$340k

-US$16m

報酬と市場: Benの 総報酬 ($USD 6.77M ) は、 US市場 ($USD 2.44M ) の同規模の企業の平均を上回っています。

報酬と収益: Benの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Ben Palleiko (58 yo)

less than a year

在職期間

US$6,772,197

報酬

Mr. Benjamin L. Palleiko, also known as Ben, has been Director and Chief Executive Officer of KalVista Pharmaceuticals, Inc. from March 07, 2024. He served as President of KalVista Pharmaceuticals, Inc. fr...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Benjamin Palleiko
CEO & Directorless than a yearUS$6.77m0.58%
$ 3.1m
Christopher Yea
Chief Development Officer8.8yrsUS$1.37m0.20%
$ 1.1m
Paul Audhya
Chief Medical Officer3.3yrsUS$1.83m0.19%
$ 1.0m
Brian Piekos
Chief Financial Officerno dataデータなしデータなし
Ryan Baker
Head of Investor Relationsno dataデータなしデータなし
Brian Krex
General Counselno dataデータなしデータなし
Jarrod Aldom
Vice President of Corporate Communicationsno dataデータなしデータなし
Rachel Morten
Senior Vice President of Regulatory Affairs & QAno dataデータなしデータなし
Michael Smith
Senior Vice President of Development5.3yrsデータなしデータなし
Nicole Sweeny
Chief Commercial Officer1.2yrsデータなしデータなし
Stephen Donnelly
Director of Finance and Company Secretaryno dataデータなしデータなし

2.3yrs

平均在職期間

51yo

平均年齢

経験豊富な経営陣: KALVの経営陣は 経験豊富 であると考えられます ( 3.3年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Benjamin Palleiko
CEO & Directorless than a yearUS$6.77m0.58%
$ 3.1m
Edward Unkart
Independent Director9.8yrsUS$136.60k0%
$ 0
Albert Cha
Independent Director16.8yrsUS$131.60k0%
$ 0
Brian J. Pereira
Independent Chairman5.6yrsUS$161.60k0%
$ 0
Nancy Stuart
Independent Director3.5yrsUS$136.60k0%
$ 0
William Fairey
Directorless than a yearUS$143.78kデータなし
Tomas Kiselak
Board Observer9.2yrsデータなしデータなし
Patrick Treanor
Independent Director2.3yrsUS$124.10k0%
$ 0

4.5yrs

平均在職期間

58.5yo

平均年齢

経験豊富なボード: KALVの 取締役会 は 経験豊富 であると考えられます ( 4.5年の平均在任期間)。